56 , T157T174 (2016)
We like to set our patients up for success by building strong diet and exercise habits while they are on the medication so that they are losing weight in a healthy way, minimizing the loss of muscle mass, and reducing rebound weight gain when they are ready to discontinue the medication
By 2026, patients have multiple FDA-recognized and physician-directed options, including injectable formulations, oral semaglutide, and compounded versions prescribed within regulated programs
However, if you have been at maximum dose for 12 or more weeks without adequate response, or if side effects prevent further dose increases, switching to tirzepatide is a reasonable next step
The AlayaCare app is easy to chart
Having this setup ready demonstrates a commitment to good laboratory practice